Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
Stock code: 300957 Stock abbreviation: Botanee Announcement number: 2026-011
Yunnan Botanee Bio-Technology Group Co., Ltd.
Summary of the 2025 Annual Report
I. Important Notice
(1) This annual report summary is derived from the full text of the annual report. To fully
understand the Company’s operating results, financial status, and future development plans,
investors should carefully read the full annual report on the media designated by the China
Securities Regulatory Commission.
(2) All directors attended the Board meeting for deliberating on this report.
(3) Tianheng Certified Public Accountants (Special General Partnership) issued a standard
unqualified opinion on the Company’s financial report for the year.
Notice of the non-standard audit opinion
□ Applicable ?Not applicable
The Company was not profitable at the time of its listing and has not achieved profitability to date
□ Applicable ?Not applicable
Profit distribution plan or capital reserve transfer plan to increase capital approved by the board
during the reporting period
?Applicable □ Not applicable
The profit distribution plan approved by the Board during this meeting is: Based on the Company’s
total share capital of 423,600,000 shares, subtracting 2,307,118 shares in the repurchase special
account that do not participate in the profit distribution, i.e., using 421,292,882 shares as the base, a
cash dividend of CNY3.50 (tax included) will be distributed for every 10 shares to all shareholders,
with 0 bonus share (tax included) and 0 share for every 10 shares transferred to all shareholders
from capital reserve.
The profit distribution plan for preferred shares approved by the Board during the reporting period
□ Applicable ?Not applicable
II. Company Overview
Stock name Botanee Stock code 300957
Stock listing exchange Shenzhen Stock Exchange
Contact person and contact information Board Secretary Securities representative
Name Wang Long Xu Minjing
No. 53, Keyi Road, Kunming High-tech No. 53, Keyi Road, Kunming High-tech
Office address
Industrial Development Zone, Kunming, Industrial Development Zone, Kunming,
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
Yunnan Province Yunnan Province
Fax 021-6232 1125 021-6232 1125
Tel. 021-6232 1125 021-6232 1125
Email ir@botanee.com ir@botanee.com
Yunnan Botanee Bio-Technology Group Co., Ltd. (hereinafter referred to as the “Company”)
focuses on the development of multiple brands, including core brand Winona as well as Winona
Baby, AOXMED, Beforteen, Za, PURE&MILD and TriPollar1. We specialize in providing
professional and effective skincare products using pure natural plant-derived active ingredients,
with a particular emphasis on sensitive skin. As a specialized cosmetics manufacturer that integrates
deeply with internet- based sales channels, our mission is to “create China’s skin health ecosystem”
by deeply understanding consumer needs, basing its products on dermatological theories, and
combining multidisciplinary technologies such as biology and botany to continuously conduct
product research and technological innovation. We strive to provide professional skincare, medical
devices and makeup products that cater to different skin needs.
We have established a foundation through offline pharmaceutical channels and implemented an
omnichannel strategy covering online platforms. With a comprehensive retail touchpoint system, we
have successfully realized cross-industry marketing (OMO) leveraging the internet and new
technologies like artificial intelligence. This has facilitated mutual penetration between offline and
online channels and achieved extensive coverage of consumer groups, which makes Botanee a
leading company in the internet+ greater health industry in China. Additionally, we capitalize on the
efficiency of the internet, the vast user traffic on mainstream e-commerce platforms, and flexible
new media marketing methods. With our strengths in online operations and high-quality products,
we have successfully seized the opportunities for rapid growth in the cosmetics industry driven by
the “Chinese domestic products” trend.
Our main product categories include facial creams, toners, face masks, serums, lotions, as well as
makeup products such as sunscreens, powders, BB creams, and makeup removers. In addition to
skincare and makeup, we are also engaged in the research, development, production, and sales of
medical devices and electronic beauty devices related to skincare. This includes medical devices
and home-use electronic radio frequency (RF) beauty devices such as hyaluronic acid repair biofilm
and hyaluronic acid repair dressings used for the protection and care of damaged skin barriers after
minimally invasive procedures.
TriPollar is limited to the Chinese mainland; the same below.
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
Winona
Winona protects sensitive skin with professional expertise, and studies Yunnan’s unique plants
based on dermatological research. Empowered by technology and evidence-based support, Winona
offers professional, precise, and safe efficacy-driven skincare solutions for sensitive skin.
Winona Baby
Inheriting the genetic essence of the parent brand Winona, Winona Baby collaborates with pediatric
dermatology experts to develop effective skincare products for babies and focuses on the eczema
treatment sector for infants and toddlers. Based on dermatological expertise and clinical experience,
Winona Baby offers a professional infant and toddler skincare brand with a simplified ingredient
and exclusive patented plant extract formulas.
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
AOXMED
Born for professional beauty, focusing on skin rejuvenation and linking medical aesthetics with
home beauty, AOXMED offers effective and safe in-clinic medical beauty and cosmetic care
combined with home-based medical-grade sequential skincare, while advocating for mindfulness in
youthfulness and promoting the right approach to prevent skin aging, achieving holistic anti-aging
for both body and mind.
Beforteen
Beforteen collaborates with dermatological experts to conduct case studies on over one million
cases, integrating AI consultations and providing personalized, unique and integrated “food +
medicine +cosmetics” solutions for the precise treatment of different types of acne.
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
Za
Za focuses on the characteristics of Asian women’s skin and offers high-performance base makeup
solutions that are multi-functional and easy to use. Za is positioned as an international light makeup
brand that allows users to effortlessly enjoy their beautiful daily life. The core products of Za
include base makeup products such as four-color sunscreen, tinted moisturizer, powders, and oil
cleanser. Its star product, the sunscreen, has been a bestseller internationally for 22 years.
PURE&MILD
As a skincare brand designed specifically for Chinese women, PURE&MILD carefully selects rare
plants from around the world, and combines advanced skincare technologies and effective
ingredients to offer consumers a gentle yet long-lasting plant-based skincare solution that
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
rejuvenates the skin. The core products of PURE&MILD include toners, lotions, and facial creams,
and the brand has been operating for 25 years.
TriPollar
Specializing in bringing professional anti-aging solutions from clinical settings to home use,
TriPollar leverages Lumenis’ over 50 years of clinic aesthetic medical technology while deeply
integrating Botanee’s dermatological science expertise. With professional energy-based medicine
technology at its core, TriPollar creates a synergistic home repair and anti-aging solution that
combines “clinical energy with photoelectric-specific skincare”. As a dermatology-grade brand
dedicated to at-home clinical anti-aging, it delivers a safe and efficient home anti-aging experience
for users.
During the reporting period, facing multiple challenges such as the slow recovery of the consumer
market, intensified industry competition, rising online traffic costs, and profound adjustments in
channel structure, Botanee adhered to the core strategy of creating a skin health ecosystem”. Guided
by “one center and two basic points” (with brand building as the center, and member operation and
omnichannel synergistic growth as the basic points), the Company achieved comprehensive
breakthroughs in areas such as brand upgrading, product innovation, intensive channel cultivation,
tackling key R&D challenges, digital transformation, supply chain quality improvement, and
organizational reform. As a result, overall operations remained steady, the multi-brand matrix
generated synergistic effects, and the positive momentum of high-quality development in core
businesses has continued to solidify.
position in dermatology
During the reporting period, the Company built a comprehensive marketing matrix, fully shifting
from pursuing “exposure” to deeply cultivating “brand equity accumulation”, ensuring the
consistency of user experience by unifying brand personality and language. During the reporting
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
period, Winona officially established its brand image as a “professional dermatology expert +
radiant lifestyle expert”, and clarified the original aspiration of returning to “beauty stems from
health”. During the reporting period, the core products of Winona maintained strong performance:
The “Winona Sensitiveness Relieving Moisturizing Tolerance-Extreme Cream” series once again
ranked first in sales within the sensitive skin cream segment. The “Winona Sunblock Milk” series
further increased its market share, establishing a refined scenario matrix covering needs from daily
commuting to outdoor activities. The Camellia-Lucent series saw steady growth, among which the
set of Camellia-Lucent Correcting Essence Lotion and Luminous Brightening Radiance Repair
Emulsion ranked TOP 1 among new toner and lotion products on Douyin. In addition, during the
reporting period, Winona successfully pioneered a new anti-aging track for sensitive skin, launching
the flagship “Silver Core” series anti-aging solution, which attracted significant market attention
upon its debut. Meanwhile, the newly upgraded Barrier Repair Essence (311 Single-Pulse Essence)
series rapidly ranked among the TOP 10 in the single-pulse essence category on Tmall.
During the reporting period, the Company continued to strengthen the core strategy of “medical
empowerment of brands”, systematically constructed and elaborated the scientific theoretical
system of its brands and products through the white paper Advancing the High-Quality
Development of Efficacy Skincare Products in China Following the NUTE Principle2 officially
released at the 6th China Sensitive Skin Summit, and completed the development of two major core
knowledge bases. During the reporting period, the Company actively participated in the Annual
Meeting of China Dermatologist Association & National Congress of Cosmetic Dermatology, and
continued to increase investment in public welfare projects such as the “525 Scientific Skincare
Week” and “919 Acne Week”, demonstrating and conveying the medical empowerment capabilities
of Botanee’s brands through forms such as professional endorsements, skin health education, and
professional free clinics. Internationally, the Company was the only Chinese brand invited to attend
the 4th ILDS World Skin Summit and actively participated in the drafting of the world’s first
consensus on visible light protection. This marks a milestone where the Company has made China’s
voice heard at the global dermatology decision-making level.
During the reporting period, Winona Baby achieved high-quality growth. By focusing on solutions
for infant and toddler eczema, it realized a sales revenue of CNY234,725,300, representing a year-
on-year increase of approximately 17.02%. Notably, revenue on the Douyin platform surged by
approximately 109.56%. Winona Baby successfully entered premium offline KA channels such as
Sam’s Club and Watsons. The core products “Soothing Hydrating Cream” and “Mild Multicare
Sunscreen both achieved steady growth, while the new products “Xiaobingdun” (Prinsepia Utilis
Microcapsule Soothing Cooling Essence Gel) and “Nuanrongrong” (Multi-Effect Plant-Based
Soothing and Moisturizing Cream) face creams became instant hits upon launch, firmly securing its
position in the first tier of functional skincare for infants.
During the reporting period, AOXMED achieved a milestone breakthrough, with sales revenue
growing over 100.00% year-on-year. Revenue from online channels surged approximately 140.90%
year-on-year, successfully marking the brand’s leap “from 0 to CNY100 million”. During the
reporting period, AOXMED adopted a core strategy of “full-process anti-aging combining medical
The NUTE scientific principles, which underpin the high-quality development of functional skincare products, mainly
comprise four aspects:
Need: Starting from addressing key pain points and unmet needs;
Unique: New mechanisms, new targets, and new outcomes;
Technology: Innovation in ingredients, formulations, and technologies;
Evidence: Based on clinical observations, with real-world efficacy validation.
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
beauty and cosmetics”, and partnered with over 600 professional clinic-based institutions
nationwide. Its premium anti-aging brand image has become deeply rooted in the market.
During the reporting period, Beforteen continued to center on its core proposition of “AI-powered
precision and effective acne treatment”, intensifying its presence on social platforms like
Xiaohongshu, with over 320 million exposures. This successfully established the association
between “Beforteen = Graded Acne Treatment” in user mindset. During the reporting period,
Beforteen successfully achieved an increase in the repurchase rate through the “medicine +
cosmetics” solution and Internet medical services.
During the reporting period, the Company successfully acquired TriPollar, laying a solid foundation
for its strategic layout in the fields of medical devices and home beauty devices. During the
reporting period, TriPollar achieved a leap in ranking from Top 15 to Top 5 in the high-end home
RF beauty device market. In the future, TriPollar will rebuild the “facial anti-aging + eye anti-aging”
product matrix, leveraging the Company’s end-to-end quality control system and the operational
capabilities of an omnichannel marketing closed loop to re-establish the image of “the leader in
bringing clinical anti-aging to home use” in user mindset.
During the reporting period, Za and PURE&MILD achieved steady operations under the
Company’s empowerment. Za has launched high-quality products across Chinese Mainland, Taiwan
of China, Hong Kong of China, and Singapore, covering a diverse range of beauty categories,
including makeup primers, base makeup, eye and lip products, and finishing products. The brand’
s hero product, its makeup primer, achieved full-channel exposure through official announcements
featuring brand ambassadors and IP collaborations, and ranked No.1 on Tmall’s best-selling list
for oil-control primers. PURE&MILD partnered with a Yunnan Specialty Plant Extraction
Laboratory to conduct research on BotanSTB Plus for anti-photoaging, with the findings
successfully published in an international academic journal. In 2025, leveraging the Key Laboratory
of Applied Enzymology at the Yangtze River Delta Institute of Tsinghua University, PURE&MILD
integrated AI-powered computational biotechnology with biopharmaceutical-grade manufacturing
technologies to incorporate its patented recombinant Type XXI collagen into the upgraded Collagen
Bouncy Anti-Wrinkle Cream 2.0 for the first time, delivering full-path anti-aging efficacy. Shortly
after its launch, Collagen Bouncy Anti-Wrinkle Cream 2.0 ranked among the Top 10 most popular
anti-aging creams on Douyin Mall.
During the reporting period, facing online traffic fragmentation and offline foot traffic challenges,
the Company actively promoted channel transformation and refined operations. While solidifying
its position in online channels, the Company saw particularly impressive performance from
emerging instant retail channels. Winona firmly maintained its top position in the functional
skincare industry within the OTC retail pharmacy channel, expanding its coverage by over 3,500
chain retail pharmacies. During the reporting period, the Company fully committed to its instant
retail channel expansion. By leveraging the mature distribution networks of KA channel partners
alongside its own branded counters, it made a strong entry into O2O platforms, securing the No. 1
position in the skincare brand category on Meituan’s instant retail business. This enabled the
Company to successfully capture the traffic dividends from both the nighttime economy and on-
demand sensitive skin scenarios.
During the reporting period, the Company continuously optimized its online channel structure.
Despite pressure on gross merchandise value in shelf-based e-commerce, the Company achieved a
significant increase in gross profit margin driven by the strong performance of influencer
livestreaming, with the sales gross margin rising by approximately 2.70 percentage points year-on-
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
year. Content-driven e-commerce benefited from customized marketplace operations and the
establishment of an influencer distribution system, delivering a year-on-year revenue growth of
approximately 17.25%. During the reporting period, the Company also implemented more refined
operations across different platforms and cities, driving impressive growth in lower-tier channels
including Pinduoduo, private domains, and distribution, while maintaining a top-tier industry
position on JD.com and Vipshop.
During the reporting period, the Company steadily expanded its overseas markets. Through multiple
models including self-operated, distribution, and agency channels, it established a presence in Hong
Kong SAR, Macao SAR, Taiwan region, and multiple countries and regions in Southeast Asia and
North America. The pace of brand internationalization has been continuously accelerating and
intensifying.
technology
During the reporting period, the Company continued to adhere to the R&D philosophy of “Targeted
Focus, In-Depth Research, Real Results”, and achieved milestone breakthroughs across
fundamental research, raw material innovation, medical devices, and global expansion.
During the reporting period, the Company continued to deeply engage in the innovative research
and development of new cosmetic raw materials, adding five new cosmetic raw material filings
during the year and bringing the cumulative number of filings to 17. The Company’s filing scale
firmly ranked first nationwide, leading the industry’s raw material innovation track. Relying on the
endowment of Yunnan’s plant resources, the Company independently completed the research and
development of 43 cosmetic raw materials and eight food raw materials, among which the
whitening raw material BTN-737, developed based on YKMB-002 and AI generative design, was
successfully included in the innovation service catalog of the National Institutes for Food and Drug
Control. The self-developed raw materials won two prestigious awards， namely the “InnoCosme
Awards 2025 for Raw Materials” and the “China Innovative Raw Material Award”. In terms of
global expansion, the Company successfully participated in In-Cosmetics Global, the world’s top
professional exhibition for cosmetic raw materials, making the international debut of its self-
developed raw materials. It showcased 11 proprietary ingredient products, demonstrating to the
global industry the innovative strength of Chinese beauty ingredients.
During the reporting period, the Company completed the filing of 31 general cosmetics products
and the registration of 10 special cosmetics products. To support overseas market expansion, the
Company also completed 13 export filings, covering regions including North America, Europe, the
Middle East, and Southeast Asia, thereby laying a solid compliance foundation for the global
expansion of its brands. During the reporting period, the Company obtained seven new Class II
medical device registration certificates, which feature sodium hyaluronate and recombinant
collagen as core components and cover various dosage forms such as liquids, gels, lotions, creams,
and dressings, further improving the synergistic product ecosystem featuring medical device and
cosmetics. Meanwhile, the Company achieved a breakthrough in Class III medical devices, marking
a milestone for Class III implantable medical devices. Both “BTN001” and “BTN002” successfully
passed registration testing, clinical trials, and quality system inspections, and have entered the
review stage of the National Medical Products Administration. In addition, a third filler-type
medical device has initiated registration testing.
In terms of global scientific research cooperation, during the Reporting Period, the Company
established a long-term Ph.D. training partnership with Saint-Louis Hospital in France. It also
deepened its research collaboration with University of Paris-Saclay on the molecular mechanisms of
neurocosmetics. In partnership with Labskin Creations, the Company co-developed two proprietary
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
Dermatological Research. Furthermore, the Company entered into a strategic partnership with an
organ-on-a-chip company affiliated with MIT, jointly exploring the application of organoids and
organ-on-a-chip technologies in cosmetic evaluation.
During the reporting period, the Company was granted 50 invention patents, 16 utility model
patents, and three design patents. It also participated in the formulation and release of four national
standards and 10 group standards, and initiated the R&D of one national standard sample. During
the reporting period, the Company published 160 academic papers, including 115 SCI-indexed
papers and 45 papers in Chinese core journals. During the reporting period, the “R&D and
Industrialization of Domestic Efficacy Skincare Products” project was shortlisted in the public
notification list for the Special Prize of the 2025 Yunnan Provincial Science and Technology Award,
“R&D and Industrial Application of Winona Efficacy Skincare Products for Sensitive Skin” won
the First Prize of the Science and Technology Progress Award of the China National Light Industry
Council, and the Company’s core brand, Winona, was selected into the first batch of “China
Premium Consumer Brands” by the Ministry of Industry and Information Technology.
development
During the reporting period, the Company’s supply chain system focused on “digital and intelligent
empowerment, supply and demand balance, quality improvement and efficiency enhancement”,
achieving remarkable results. The Company’s proportion of independent production continued to
increase steadily, effectively ensuring the capacity release of self-operated factories and the stability
of product gross profit margins. By deepening the S&OP mechanism and lean management,
inventory turnover efficiency was significantly optimized by approximately 16.97% year-on-year.
In addition, the Company implemented product lifecycle management. As of the end of the
reporting period, the number of long-tail and inefficient inventory products was reduced by nearly
and AI
During the reporting period, the Company’s Digital Technology Center transitioned from “building
platforms” to “creating value”. The Company’s internal AI platform ChatBTN was successfully
launched, covering core business scenarios across multiple departments. The Consumer Data
Platform (CDP) was fully launched, and data extraction efficiency improved from the “day” level to
the “minute” level. The integrated business and finance platform was fully established, achieving
the same source of business and financial data as well as procedure connectivity. During the
reporting period, the membership middle platform achieved remarkable results. The Company’s
total registered members across all channels surpassed 46 million, representing a year-on-year
increase of approximately 10%. Leveraging the consumer data platform, the retention rate of
existing members increased by approximately 8%, and the conversion rate of new members
increased by approximately 5%. During the reporting period, the Company released its first
Member Points White Paper, driving the member points system from extensive operations toward
intelligent risk control and precision marketing. During the reporting period, the Company’s self-
developed supply chain planning and management platform was launched, initially realizing the
deployment of over 20 smart scenarios, including AI-powered intelligent inspection and automated
replenishment.
business for good
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
During the reporting period, guided by the philosophy of “all for the health and beauty of humans
and nature ” , the Company deeply integrated ESG into its strategy. Leveraging Yunnan ’ s rich
botanical resources, it has built a closed-loop model combining ecological conservation with green
industrialization, setting a benchmark for sustainability in the beauty industry. In terms of
environmental aspect, the Company continues to advance biodiversity conservation, establishing
approximately 10.42 mu of ecological demonstration plots in the Hutiao Gorge area and carrying
out the reintroduction of rare alpine plant species to strengthen mountain ecosystem resilience. In
clean energy, the central factory generated approximately 1.59 million kWh of solar power for self-
consumption annually. Significant progress was made in green packaging reduction, with 3.5484
million inner boxes and 2.106 million paper leaflets eliminated during the year, alongside the
recycling of 3.17 million empty bottles. RSPO-certified raw materials accounted for approximately
warehousing and logistics network by promoting new energy transportation and energy-efficient
storage, and continued to conduct full lifecycle carbon footprint assessments to drive emissions
reduction across the value chain. In terms of social aspect, the Company remains committed to
public welfare. During the reporting period, it contributed CNY13.678 million (including cash and
in-kind donations), supporting 31 initiatives. The Company has continued its “ Winona Smile
Sunshine Program ” for the 10th consecutive year, conducting free medical consultations and
public education campaigns in high-UV regions such as Shangri-La. The “Winona Baby” brand
also advanced its public welfare initiative supporting children with atopic dermatitis (AD), reaching
over 180 million people through educational outreach. Meanwhile, the Company has fostered an
inclusive workplace, with women accounting for 56% of management positions, and has placed
strong emphasis on talent development, with employees receiving an average of over 108 training
hours per year. In terms of governance aspect, the Company has maintained an A rating for
information disclosure from the Shenzhen Stock Exchange for the third consecutive year. During
the reporting period, it was included in Wind ’ s Top 100 Best ESG Practices among Chinese’s
Listed C0ompanies and received an “AA” ESG rating. It was also recognized among the TOP
“ AAA ” rating. Looking ahead, the Group will continue to empower ecological development
through technology and uphold a long-term approach, expanding its sustainable mountain
ecosystem model and delivering an Eastern approach to green beauty solutions to the global market.
During the reporting period, the Company actively responded to the complex and changing market
environment, striving to overcome various adverse factors, and achieved certain results in its
operational performance. During the reporting period, the Company achieved operating revenue of
approximately CNY5,358,638,800, a year-on-year decrease of approximately 6.58%; a net profit
attributable to the shareholders of the listed company of approximately CNY505,719,700, a slight
year-on-year increase of approximately 0.53%; a net profit attributable to the shareholders of the
listed company after excluding non-recurring gains and losses of approximately CNY356,146,600,
a significant year-on-year increase of approximately 48.22%; a sales gross profit margin of
approximately 74.46%, a year-on-year increase of approximately 0.72 percentage points; and a net
sales margin attributable to shareholders of the listed Company of approximately 9.44%, a year-on-
year increase of approximately 0.67 percentage points. During the reporting period, although the
Company’s sales volume declined slightly, profits (gross profit and net profit) showed a steady
trend, and profitability has improved with recurring profit achieving a more significant
improvement. During the reporting period, fluctuations in the Company’s revenue and profit were
primarily attributable to a combination of the following factors: First, increased investment in brand
building, channel development, and marketing expenses to consolidate the Company’s market
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
position and incubate new brands and products; second, strategic investments to respond to market
changes and channel transformation, including the active expansion of new growth drivers such as
instant retail and content-driven e-commerce; third, necessary expenditures to enhance the
autonomy and controllability of supply chain and to strengthen product innovation. In addition,
asset impairment provisions resulting from the underperformance of acquired targets relative to
expectations also had a certain impact on performance. Meanwhile, during the reporting period, the
Company’s cash flow remained healthy, the quality and efficiency of operating cash flow further
improved, and operating fundamentals were solid. Looking ahead, the Company will stay
committed to long-termism, focus on its advantageous segments, and strengthen omnichannel
synergy. By continuously driving cost reduction and efficiency enhancement, organizational
transformation, and refined operations, the Company aims to achieve both healthy brand
development and higher profit quality, facilitating its transition from scale-driven growth to value-
driven growth.
Whether the Company retrospectively adjusted or restated accounting data for previous year
□ Yes ?No
Unit: CNY
YoY
increase/decrease
End of 2025 End of 2024 End of 2023
compared with the
previous year
Total assets 8,341,346,880.58 8,303,551,892.22 0.46% 7,506,930,342.79
Net assets attributable to our
shareholders
YoY
increase/decrease
compared with the
previous year
Operating revenue 5,358,638,784.56 5,735,865,254.21 -6.58% 5,522,168,263.00
Net profit attributable to our
shareholders
Net profit attributable to our
shareholders after deducting non- 356,146,562.10 240,289,033.33 48.22% 618,058,791.53
recurring gains and losses
Net cash flow from operating
activities
Basic earnings per share
(CNY/share)
Diluted earnings per share
(CNY/share)
Weighted average return on net Decreased by 0.33
assets percentage points
Unit: CNY
Q1 Q2 Q3 Q4
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
Operating revenue 948,763,070.82 1,423,079,513.94 1,092,432,006.28 1,894,364,193.52
Net profit attributable to our
shareholders
Net profit attributable to our
shareholders after deducting non- 20,924,775.03 161,692,314.46 1,148,777.26 172,380,695.35
recurring gains and losses
Net cash flow from operating
-68,652,234.98 415,580,994.65 94,950,854.20 534,716,125.97
activities
Whether the aforesaid financial indicators or their sum are significantly different from relevant
financial indicators disclosed by the Company in its quarterly and semi-annual reports
□ Yes ?No
Rights, and the Shareholding of the Top 10 Shareholders
Unit: share
Total Total Total number
number of number of of preferred
ordinary preferred shareholders
Ordinary Shareholders
shareholders shareholders with restored
shareholders holding
at the end of with voting rights as
as of the special
end of the voting
prior to the voting the month
reporting shares (if
disclosure rights at the prior to the
period any)
of the end of the disclosure of
annual reporting the annual
report period report
Shareholding of the top 10 shareholders (excluding shares loaned through refinancing)
Number Pledged, marked or
of shares frozen shares
Shareholding Number of
Shareholder name Shareholder type subject to
ratio shares held Status of
trading Quantity
shares
restriction
Kunming Nuona Technology Co., Domestic non-state-
Ltd. owned corporation
Tianjin Sequoia Juye Equity
Domestic non-state-
Investment Partnership (Limited 7.62% 32,272,757.00 N/A
owned corporation
Partnership)
Yunnan Haqisheng Enterprise Domestic non-state-
Management Co., Ltd. owned corporation
Domestic non-state-
Xiamen Zhenli Consulting Co., Ltd. 2.47% 10,467,669.00 N/A
owned corporation
Hong Kong Securities Clearing Overseas legal
Company Limited person
Overseas legal
Kuwait Investment Authority 1.04% 4,390,658.00 N/A
person
Industrial and Commercial Bank of
China Co., Ltd. — E Fund GEM
Miscellaneous 0.86% 3,663,991.00 N/A
Traded Open-End Index Securities
Investment Fund
National Social Security Fund
Miscellaneous 0.81% 3,417,711.00 N/A
Portfolio 118
Industrial and Commercial Bank of
China Limited — CSI Main
Consumer Exchange-Traded Open- Miscellaneous 0.73% 3,084,657.00 N/A
End Index Securities Investment
Fund
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
Agricultural Bank of China Co.,
Ltd. – CSI 500 Exchange-Traded
Miscellaneous 0.71% 3,021,200.00 N/A
Open-End Index Securities
Investment Fund
Both Kunming Nuona Technology Co., Ltd. and Yunnan Haqisheng Enterprise Management
Explanations of relationships
Co., Ltd. are enterprises controlled by the Company’s actual controller, Guo Zhenyu. Besides,
between or concerted actions of the
no connected relationship and action in concert between other shareholders is known to the
aforementioned shareholders
Company.
The situation of shareholders holding more than 5% of shares, the top 10 shareholders, and the top
□ Applicable ?Not applicable
Changes occurred in the top 10 shareholders and the top 10 shareholders of unrestricted tradable
shares compared with the previous period due to shares loan through refinancing/return
□ Applicable ?Not applicable
Whether the Company has differential voting rights arrangements
□ Applicable ?Not applicable
Shareholders
□ Applicable ?Not applicable
Actual Controller in the Form of a Block Diagram
GUO ZHENYU
Hanson Cosmeceutical (Hong Kong) Company Limited
Outside the Chinese mainland (including Hong
Kong, Macao, and Taiwan)
Within the Chinese mainland (excluding
Hong Kong, Macao, and Taiwan) Kunming Nuona Technology Yunnan Haipo Enterprise Management Co., Ltd.
Co., Ltd.
Yunnan Haqisheng Enterprise Management Co.,
Ltd.
Yunnan Botanee Bio-Technology Group Co., Ltd.
□ Applicable ?Not applicable
Yunnan Botanee Bio-Technology Group Co., Ltd. Summary of the 2025 Annual Report
III. Significant Matters
For details, please refer to the 2025 Annual Report of Yunnan Botanee Bio-Technology Group Co.,
Ltd. (2026-013) disclosed on CNINFO (http://www.cninfo.com.cn).
首页
微信公众号
证券之星APP
